Sally Samy Mohamed

Dr. Sally Samy Mohamed


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
SGSherif M Gamal
Sherif M Gamal
SMSally Samy Mohamed
Sally Samy Mohamed
MTMarwa Tantawy
Marwa Tantawy
ISIbrahem Siam
Ibrahem Siam
ASAhmed Soliman
Ahmed Soliman
MNMarwa Hassan Niazy
Marwa Hassan Niazy
Objectives: This study aims to examine the frequency and clinical association of lupus-related vasculitis in patients with systemic lupus erythematosus (SLE). Patients and methods: We retrospectively analyzed medical records of a total of 565 SLE patients (42 males, 523 females; mean age: 32.7±9.5 years; range, 13 to 63 years) between January 2017 and February 2020. Demographic, clinical data, and laboratory data and treatment modalities applied were recorded. Lupus-related vasculitis and its different types were documented, and the patients with vasculitis were compared with those without vasculitis. Results: The mean disease duration was 8.9±6.3 years. Vasculitis associated with lupus was found in 191 (33.45%) patients. Cutaneous vasculitis was found in 59.2%, visceral vasculitis in 34.0%, and both in 6.8% of total vasculitis patients. The patients with vasculitis had a longer disease duration (p=0.01), were more likely to have juvenile onset (p=0.002), livedo reticularis (p

16 March 2023 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
NANasser Keshar Abdzlnaby
Nasser Keshar Abdzlnaby
SGSherif M. Gamal
Sherif M. Gamal
AAAlkhateeb Alkemary
Alkhateeb Alkemary
MAMarwa Abdo
Marwa Abdo
ISIrene M. Sabry
Irene M. Sabry
SMSally Samy Mohamed
Sally Samy Mohamed

13 November 2022 in Chronic Illness
Verified
Journal Article
Closed access
SGSherif M Gamal
Sherif M Gamal
AMAbir Mokbel
Abir Mokbel
MNMarwa H. Niazy
Marwa H. Niazy
FEFatema T Elgengehy
Fatema T Elgengehy
NENora Y Elsaid
Nora Y Elsaid
BEBassel El-Zorkany
Bassel El-Zorkany
Objective: To study the prevalence and impact of comorbidities among a cohort of patients with systemic lupus erythematosus (SLE). Methods: This study is retrospective, multicenter including 902 Egyptian patients with SLE. Medical records were reviewed for demographic data, clinical characteristics, routine laboratory findings, immunological profile, and medications. Moreover, SLE Disease Activity Index (SLEDAI), and the Systemic Lupus International Collaborating Clinics/American College Rheumatology Damage Index scores were calculated. Results: Comorbidities were found in 75.5% of the studied group with hypertension and dyslipidemia as the most frequent comorbidities (43.1% and 40.1%, respectively), followed by sicca features, avascular necrosis, diabetes, osteoporosis and renal failure (11.5%,9%, 9%,8.9%, and 7.1%, respectively). Multivariate regression model showed statistically significant relation between the presence of comorbid condition and each of age ( P = 0.006), disease duration ( P = 0.041), SLEDAI at onset ( P < 0.001), cyclophosphamide intake ( P = 0.001), and cumulative pulse intravenous methylprednisone ( P < 0.001). Also, when adjusted to age and sex, those with multiple comorbid conditions had 18.5 increased odds of mortality compared to those without comorbidities (odds ratio (OR), 95% confidence interval (CI) = 18.5 (6.65–51.69)]. Conclusion: Patients with SLE suffer from several comorbidities, with an increasing risk with age, longer disease duration, higher SLEDAI at onset, cyclophosphamide intake and cumulative pulse intravenous methylprednisone. Risk of mortality is exponentiated with multiple comorbidities.

24 December 2020 in Current Rheumatology Reviews
Verified
Journal Article
Closed access
PDF file
GEGeilan Abd El-Moniem
Geilan Abd El-Moniem
KEKamal El-Garf
Kamal El-Garf
NSNesreen Sobhy
Nesreen Sobhy
SESally Elmaghraby
Sally Elmaghraby
SMSally Samy Mohamed
Sally Samy Mohamed
Objective: To study the clinical and laboratory features of Antiphospholipid Syndrome (APS) in a cohort of Egyptian patients and compare between primary and secondary type on the basis of clinical and immunological pattern. Patients and Methods: We reviewed the medical records of 148 antiphospholipid syndrome patients following in Rheumatology and Rehabilitation department, Cairo University. Clinical and immunological data were recorded; subsequently, our patients were compared based on the type of APS, patient’s age and sex. Results: The cohort consisted of 148 patients, 135 females (91.2%) and 13 males (8.8%). The mean age at onset was 23.6 ±7.66 years. 28.4% of patients had primary while, 71.6% of patients had secondary APS. : Patients with secondary APS presented more frequently with the following manifestations compared to patients with primary APS: systemic manifestations (56.6% versus 4.8%, P-value: 0.00), venous thrombosis (41.5% versus 19%, P-value: 0.009), cutaneous vasculitis (19.8% versus 4.8%, P-value: 0.023), thrombocytopenia (37.7% versus 11.9%, P-value: 0.002) and hemolytic anemia (28.3% versus 4.8%, P-value: 0.002). On the other hand, total obstetric manifestations were more common in primary APS (92.5% versus 75%, P-value: 0.007). : Juvenile onset APS presented more frequently with systemic (68.8%, p-value: 0.02), neurological (62.5%, p-value: 0.01) and renal manifestations (31.3%, p-value: 0.005). No statistically significant difference was found between males and females in our cohort. Conclusion: APS has broad spectrum manifestations, which may vary according to the patient’s age at disease onset and association with other diseases. Further more, different ethnicities may show different presentations.

10 January 2024 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
SMSally Samy Mohamed
Sally Samy Mohamed
SGSherif Mohamed Gamal
Sherif Mohamed Gamal
AMAbir Mokbel
Abir Mokbel
AAAlkhateeb Kadery Alkamary
Alkhateeb Kadery Alkamary
ISIbrahem Siam
Ibrahem Siam
FEFatema Talaat Elgengehy
Fatema Talaat Elgengehy

13 May 2022 in Egyptian Rheumatology and Rehabilitation
Verified
Journal Article
Open access
PDF file
YMYasser El Miedany
Yasser El Miedany
SSS. Salah
S. Salah
HLH. Lotfy
H. Lotfy
MGM. El Gaafary
M. El Gaafary
HAH. Abdulhady
H. Abdulhady
MAM. H. Abu-Zaid
M. H. Abu-Zaid
Background: These updated guidelines aimed to provide appropriate and convenient guidelines for the treatment of various types of juvenile idiopathic arthritis (JIA). Using the Delphi technique, this study was conducted to reach expert consensus on a treat-to-target management strategy for JIA. According to the PICO (patient/population, intervention, comparison, and outcomes) approach, the preliminary scientific committee identified a total of 17 key clinical questions. To assemble evidence on the advantages and dangers associated with JIA treatments, an evidence-based, systematic literature review was conducted. Researchers and clinicians with experience in JIA management were identified by the core leadership team. To establish a consensus on the management suggestions for JIA patients, a Delphi approach (2 rounds) was used. Results: An online survey was applied to the expert panel (n = 27), and 26 of them completed both rounds. At the conclusion of round 2, a total of eighteen (18) recommendation items were gathered, which were divided into four sections to address the four key JIA categories. The percentage of those who agreed with the recommendations (ranks 7–9) ranged from 83.2 to 100% (average 86.8%). The phrasing of all 18 clinical standards identified by the scientific committee was agreed upon (i.e. 75% of respondents strongly agreed or agreed). Algorithms have been proposed for the management of JIA polyarthritis, oligoarthritis, and systemic JIA. Conclusion: A wide and representative panel of experts initiated a consensus about the management of JIA. The created guidelines give a complete approach to the management of JIA for all healthcare professionals involved in its management, as well as a means of monitoring and evaluating these guidelines on a regular basis.